Page last updated: 2024-11-06

vanadyl sulfate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Vanadyl sulfate (VOSO4) is a blue-green crystalline solid that is soluble in water. It is a common reagent in vanadium chemistry and is used in a variety of applications, including as a catalyst, a pigment, and a component of some batteries. Vanadyl sulfate can be synthesized by reacting vanadium pentoxide with sulfuric acid. It is a potent inhibitor of tyrosine phosphatases, which are enzymes that play a role in regulating cellular signaling pathways. This property has led to the study of vanadyl sulfate as a potential therapeutic agent for conditions such as diabetes and cancer. Vanadyl sulfate has also been investigated for its potential as a fertilizer, as it can be absorbed by plants and used in their metabolism. It is studied extensively due to its diverse applications and potential therapeutic and industrial uses.'

Cross-References

ID SourceID
PubMed CID34007
CHEBI ID33146
MeSH IDM0105150

Synonyms (44)

Synonym
16229-43-9
vanadium oxide sulfate (vo(so4))
ccris 4121
c.i. 77940
vanadyl sulfate (vo(so4))
vanadyl sulfate (vso5)
vanadium, oxysulfato-
vanadium, oxosulfato-
hsdb 1026
ai3-52156
un2931
einecs 248-652-7
vanadium, oxo(sulfato(2-)-o)-
ci 77940
vanadium, oxo(sulfato(2-)-kappao)-
oxovanadium(iv) sulfate
v(iv)oso4
voso4
27774-13-6
vanadyl sulfate
oxidovanadium(2+) sulfate
vanadic sulfate
vanadium oxysulfate
vanadium oxide sulphate
CHEBI:33146
vanadin(iv) oxide sulfate
oxovanadium(2+) sulfate
oxo[sulfato(2-)-kappao]-vanadium
oxo[sulfato(2-)-o]-vanadium
ccris 7238
ec 248-652-7
unii-6du9y533fa
vanadyl sulfate [un2931] [poison]
vanadyl sulfate 3-hydrate
DTXSID4021428
vanadium(iv) sulfate oxide
mfcd00011460
vanadylsulphate
vanadium sulphate oxide
Q413634
UUUGYDOQQLOJQA-UHFFFAOYSA-L
vanadyl monosulfate
vanadyl trisulfate
oxovanadium(2+);sulfate

Research Excerpts

Overview

Vanadyl sulfate (VOSO(4) is an oxidative form of vanadium. It has been shown to reduce hyperglycemia and insulin resistance.

ExcerptReferenceRelevance
"Vanadyl sulfate (VOSO(4)) is an oxidative form of vanadium that in vitro and in animal models of diabetes has been shown to reduce hyperglycemia and insulin resistance. "( Vanadyl sulfate improves hepatic and muscle insulin sensitivity in type 2 diabetes.
Cukier, S; Cusi, K; DeFronzo, RA; Puchulu, FM; Redondo, JC; Torres, M, 2001
)
3.2

Treatment

Vanadyl sulfate treatment increased the nuclear translocation of Nrf2 and the accumulation of phosphorylated NRF2. Vanadyl sulphate was more effective than insulin in restoring basal enzyme activity, the stimulations exerted by stimulatory inputs on adenylyl cyclase and the G-protein levels.

ExcerptReferenceRelevance
"Vanadyl sulfate treatment increased the nuclear translocation of Nrf2 and the accumulation of phosphorylated Nrf2."( Increased glutathione synthesis following Nrf2 activation by vanadyl sulfate in human chang liver cells.
Hyun, JW; Kang, KA; Kim, AD; You, HJ; Zhang, R, 2011
)
1.33
"Vanadyl sulfate and insulin treatments restored the augmented basal enzyme activity, the stimulations exerted by stimulatory inputs on adenylyl cyclase and the G-protein levels to various degrees, however, vanadyl sulfate was more effective than insulin."( Reversal of defective G-proteins and adenylyl cyclase/cAMP signal transduction in diabetic rats by vanadyl sulphate therapy.
Anand-Srivastava, MB; McNeill, JH; Yang, XP,
)
0.85
"Vanadyl sulfate treatment normalized plasma glucose and glycosylated haemoglobin levels in streptozotocin-diabetic rats to values observed for non-diabetic rats."( Normalization of hyperglycaemia by oral vanadyl sulfate does not reverse diabetes-induced protection against cisplatin nephrotoxicity in streptozotocin-diabetic rats.
Cacini, W; Sarangarajan, R, 1999
)
1.29
"Vanadyl sulfate (3-4 wk treatment or after 5-6 h in vitro) enhanced the sustained K(+) current."( Insulin resistance and the modulation of rat cardiac K(+) currents.
Ewart, HS; Severson, D; Shimoni, Y, 2000
)
1.03
"Vanadyl sulfate treatment lowered the plasma total cholesterol (223 +/- 14 vs."( Vanadyl sulfate improves hepatic and muscle insulin sensitivity in type 2 diabetes.
Cukier, S; Cusi, K; DeFronzo, RA; Puchulu, FM; Redondo, JC; Torres, M, 2001
)
2.47
"Treatment with vanadyl sulfate reversed these effects."( Protective effect of vanadyl sulfate on skin injury in streptozotocin-induced diabetic rats.
Tunali, S; Yanardag, R, 2013
)
1.05
"Treatment with vanadyl sulfate reversed these effects."( Effects of vanadyl sulfate on kidney in experimental diabetes.
Bolkent, S; Karabulut-Bulan, O; Tunali, S; Yanardag, R, 2003
)
1.05
"Posttreatment with vanadyl sulfate significantly reduced the infarct size and significantly decreased the elevated left ventricular end diastolic pressure, improved left ventricular developed pressure, and left ventricular contractility (+/- dP/dt) after 72-h reperfusion in a dose-dependent manner."( Cardioprotective effect of vanadyl sulfate on ischemia/reperfusion-induced injury in rat heart in vivo is mediated by activation of protein kinase B and induction of FLICE-inhibitory protein.
Bhuiyan, MS; Fukunaga, K; Kasahara, J; Moriguchi, S; Shioda, N; Takada, Y, 2008
)
0.96
"Pretreatment with vanadyl sulfate, followed by transfer to a HE diet, significantly delayed the onset of hyperglycemia."( Treatment of diabetes with vanadium salts: general overview and amelioration of nutritionally induced diabetes in the Psammomys obesus gerbil.
Bar-On, H; Khamaisi, M; Nachliel, I; Shafrir, E; Spielman, S; Ziv, E,
)
0.45

Toxicity

ExcerptReferenceRelevance
" Although these compounds are very toxic in V79 cells, no mutagenic effect was observed in the presence or in the absence of S9 fraction."( Genotoxicity of vanadium compounds in yeast and cultured mammalian cells.
Bronzetti, G; Del Carratore, R; Della Croce, C; Fiorio, R; Galli, A; Giromini, L; Morichetti, E; Rosellini, D; Vellosi, R, 1991
)
0.28
" The following LD50 (14-day) were determined: NaVO3, 98."( Acute toxicity of vanadium compounds in rats and mice.
Domingo, JL; Llobet, JM, 1984
)
0.27
" This suggests that the final transforming activity response is dependent on the intracellular GSH-mediated mechanism of reduction of vanadium(V) to vanadium(IV): (i) the extent to which vanadium(V) should be bioreduced to less toxic vanadium(IV) via intracellular GSH is a key point in determining the intensity of the observed neoplastic action; (ii) the carcinogenic potential of vanadium(V) should be strictly dependent on its intracellular persistence which could lead to changes in normal metabolic patterns of vanadium(V) in the oxidized form due to lack of GSH-mediated reduction."( The intensity of vanadium(V)-induced cytotoxicity and morphological transformation in BALB/3T3 cells is dependent on glutathione-mediated bioreduction to vanadium(IV).
Casella, L; Devos, S; Fischbach, M; Pintar, A; Pozzi, G; Sabbioni, E, 1993
)
0.29
" The toxic effect in fly adult was to compare any differences in the sensitivity of males (white) and female (oregon), observing the higher sensitivity of the males."( [Genotoxic effects of vanadyl sulfate in Drosophila melanogaster].
Barrera Ferrer, SM; Villalobos Cabrera, HD, 1998
)
0.61
"Vanadium is effective and safe for long- term use in type 1 diabetic patients."( Long- term efficacy and safety of vanadium in the treatment of type 1 diabetes.
Dehghani, GA; Omrani, GR; Soveid, M, 2013
)
0.39

Pharmacokinetics

ExcerptReferenceRelevance
"Vanadium pharmacokinetic parameters and oral bioavailability were determined after administration of vanadyl sulfate, an antidiabetic agent, to male Wistar rats."( Vanadium pharmacokinetics and oral bioavailability upon single-dose administration of vanadyl sulfate to rats.
Azay, J; Brès, J; Cabanis, JC; Cros, G; Krosniak, M; Serrano, JJ; Teissedre, PL, 2001
)
0.75
" Pharmacokinetic analysis demonstrated that these capsules enhance the bioavailability of pharmacologically active vanadyl species."( Pharmacokinetic study and trial for preparation of enteric-coated capsule containing insulinomimetic vanadyl compounds: implications for clinical use.
Fugono, J; Sakurai, H; Yasui, H, 2004
)
0.32

Bioavailability

Vanadium pharmacokinetic parameters and oral bioavailability were determined after administration of vanadyl sulfate, an antidiabetic agent, to male Wistar rats. To find safer and more effective dosages, we have developed an enteric-coated capsule containing solid vanadly sulfate (ECC/VS), which enhances the bioavailability of vanadsulfate.

ExcerptReferenceRelevance
"Vanadium pharmacokinetic parameters and oral bioavailability were determined after administration of vanadyl sulfate, an antidiabetic agent, to male Wistar rats."( Vanadium pharmacokinetics and oral bioavailability upon single-dose administration of vanadyl sulfate to rats.
Azay, J; Brès, J; Cabanis, JC; Cros, G; Krosniak, M; Serrano, JJ; Teissedre, PL, 2001
)
0.75
" However, owing to low bioavailability of VS and the development of mild gastrointestinal symptoms and side-effects in some subjects, it is necessary to design more effective and safer dosages of VS."( Enteric-coating capsulation of insulinomimetic vanadyl sulfate enhances bioavailability of vanadyl species in rats.
Fugono, J; Sakurai, H; Yasui, H, 2002
)
0.57
" Pharmacokinetic analysis demonstrated that these capsules enhance the bioavailability of pharmacologically active vanadyl species."( Pharmacokinetic study and trial for preparation of enteric-coated capsule containing insulinomimetic vanadyl compounds: implications for clinical use.
Fugono, J; Sakurai, H; Yasui, H, 2004
)
0.32
" To find safer and more effective dosages, we have developed an enteric-coated capsule containing solid vanadyl sulfate (ECC/VS), which enhances the bioavailability of vanadyl sulfate to almost double that of vanadyl sulfate solution."( Improvement of diabetic states in streptozotocin-induced type 1 diabetic rats by vanadyl sulfate in enteric-coated capsules.
Fugono, J; Sakurai, H; Yasui, H, 2005
)
0.77
" Overall, data indicate scarce bioavailability for orally administered tetravalent vanadium, and lack of significant genotoxic potential in vivo."( Evaluation of genotoxicity of oral exposure to tetravalent vanadium in vivo.
Cordelli, E; Crebelli, R; Fresegna, AM; Leopardi, P; Siniscalchi, E; Veschetti, E; Villani, P, 2007
)
0.34
"The main objective of this study was to unravel the chemical reactions and processes dictating the potential bioavailability of vanadium (V)."( Impact of soil pH and organic matter on the chemical bioavailability of vanadium species: The underlying basis for risk assessment.
Hartikainen, H; Metzler, M; Reijonen, I, 2016
)
0.43

Dosage Studied

BMOV was 2 to 3 times as potent as vanadyl sulfate.

ExcerptRelevanceReference
" An oral dose-response curve showed that BMOV was 2 to 3 times as potent as vanadyl sulfate."( Comparison of the glucose-lowering properties of vanadyl sulfate and bis(maltolato)oxovanadium(IV) following acute and chronic administration.
McNeill, JH; Orvig, C; Yuen, VG, 1995
)
0.78
"1 h for the two dosage levels, respectively."( Vanadium pharmacokinetics and oral bioavailability upon single-dose administration of vanadyl sulfate to rats.
Azay, J; Brès, J; Cabanis, JC; Cros, G; Krosniak, M; Serrano, JJ; Teissedre, PL, 2001
)
0.53
" Although Cmax values were unchanged by the dosage forms, Tmax and MRT values associated with the enteric-coating capsulation were prolonged when compared with those observed with use of gelatin capsules (GC)."( Enteric-coating capsulation of insulinomimetic vanadyl sulfate enhances bioavailability of vanadyl species in rats.
Fugono, J; Sakurai, H; Yasui, H, 2002
)
0.57
" Mice were dosed with either PM sample, uranyl acetate, or vanadyl sulfate via aspiration (100 µg), with assessments of pulmonary and vascular toxicity 24 h later."( Respirable Uranyl-Vanadate-Containing Particulate Matter Derived From a Legacy Uranium Mine Site Exhibits Potentiated Cardiopulmonary Toxicity.
Ali, AM; Avasarala, S; Brearley, A; Campen, MJ; Cerrato, JM; Erdely, A; Harmon, M; Herbert, G; Kodali, V; Kunda, NK; Lin, Y; Muttil, P; Ordonez Suarez, Y; Sanchez, B; Shoeb, M; Shuey, C; Tyler, CR; Wheeler, A; Zychowski, KE, 2018
)
0.72
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
vanadium coordination entity
metal sulfateSulfate salts where the cation is a metal ion.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (189)

TimeframeStudies, This Drug (%)All Drugs %
pre-199016 (8.47)18.7374
1990's76 (40.21)18.2507
2000's58 (30.69)29.6817
2010's33 (17.46)24.3611
2020's6 (3.17)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 39.99

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index39.99 (24.57)
Research Supply Index5.34 (2.92)
Research Growth Index4.97 (4.65)
Search Engine Demand Index108.11 (26.88)
Search Engine Supply Index3.66 (0.95)

This Compound (39.99)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials9 (4.52%)5.53%
Reviews4 (2.01%)6.00%
Case Studies1 (0.50%)4.05%
Observational0 (0.00%)0.25%
Other185 (92.96%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Effect of Vanadium on Insulin Sensitivity in Patients With Impaired Glucose Tolerance [NCT00561132]Phase 314 participants (Actual)Interventional2003-11-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]